Altimmune, Inc. (ALT) Stock Grade

About Altimmune, Inc.'s fundamentals

Altimmune is a pre-revenue or early-stage biotechnology company with a market capitalization of $575.6 million that reported a net loss in its latest annual statement, reflected in its negative net margin of -214,861%. The company showed strong revenue growth of 105% year-over-year, indicating momentum in commercial activity or licensing arrangements, though this growth has not yet translated to profitability. Traditional valuation metrics like P/E ratio and return on equity are not meaningful given the company's loss-making status. As a development-stage biotech firm, the company's financial profile is typical of companies in clinical or early commercialization phases, where losses are common before achieving sustained profitability.